Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 6/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3324495 | 1.00 | KLK7 (0.36) | KLK7KLK5MMP3ADAM17PRSS1 | |
| SCHEMBL10623957 | 0.82 | CA1 (0.36) | GLA | |
| SCHEMBL2132635 | 0.78 | KLK7 (0.33) | KLK7KLK5USP2SMN1; SMN2 | |
| SCHEMBL2132631 | 0.78 | KLK7 (0.33) | KLK7KLK5USP2SMN1; SMN2 | |
| SCHEMBL3321284 | 0.76 | KLK7 (0.36) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL13205498 | 0.76 | KLK7 (0.57) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL27527337 | 0.76 | KLK7 (0.57) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL8021097 | 0.75 | CHRM2 (0.42) | KLK7KLK5MMP3ADAM17USP2 | |
| SCHEMBL7609856 | 0.75 | USP2 (0.35) | KLK7USP2SMN1; SMN2NR1H2 | |
| SCHEMBL5963617 | 0.75 | KLK7 (0.36) | KLK7KLK5MMP3ADAM17USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506734-B1 | Treatment of oncoses, comprising administering to a mammal in need thereof an effective amount inhibiting tumor growth in a mammal, comprising administering an effective amount of a compound | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-14 | — | — | US | disclosed |
| US-6492335-B1 | Glycoconjugates from modified camptothecin derivatives (20-O-linkage) | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-10 | — | — | US | disclosed |
| CN-1335301-A | 3-cyano-2, 4, 5-trifluorobenzoic acid and derivatives thereof and application thereof | BAYER AG (DE) | 2002-02-13 | — | — | CN | disclosed |
| CN-1073112-C | Optionally substituted 8-cyano-1-cyclopropyl-7- (2, 8-diazabicyclo [4.3.0] non-8-yl) -6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid and derivatives thereof | BAYER AG (DE) | 2001-10-17 | — | — | CN | disclosed |
| CN-1255926-A | 20(S) -camptothecin glycoconjugates | BAYER AG (DE) | 2000-06-07 | — | — | CN | disclosed |
| CN-1211984-A | Optionally substituted 8-cyano-1-cyclopropyl-7- (2, 8-diazabicyclo [4.3.0] non-8-yl) -6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid and derivatives thereof | BAYER AG (DE) | 1999-03-24 | — | — | CN | disclosed |